Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACTM-838 in advanced solid tumors
NCT06336148Phase 1Terminated
- Sponsor
- Actym Therapeutics
- Start
- Jun 2024
- Primary completion
- Aug 2025
- Modality
- Gene Editing, Gene Silencing, Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of ACTM-838 in solid tumor, sponsored by Actym Therapeutics. Primary endpoints: Adverse Events at 1 year and Dose Limiting Toxicities at 28 days. Started Jun 2024; status: terminated.
02
Drugs
ACTM-838
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06336148.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06336148.